Ibuprofen Plain- @ ( *** ) Propion deriv - (FDC- List )- (1974)
Drug Name:Ibuprofen Plain- @ ( *** ) Propion deriv - (FDC- List )- (1974)
List Of Brands:
Indication Type Description:
Drug Interaction
Indication
Adverse Reaction
Contra-Indications
Dosages/ Overdosage Etc
Other Information
Patient Information
Pharmacology/ Pharmacokinetics
Interaction with Food
Pregnancy and lactation
Drug Interaction:
NSAIDs include-
Propionic acid- Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Naproxen Sodium, Oxaprozin
Acetic acids- Diclofenac sodium, Etodolac, Indomethicin, Ketorolac, Nabumetone, Sulindac, Tolmetin
Fenamates (anthralic acids) - Meclofenamate, Mefenamic acxid
Oxicams- Piroxicam
Refer- Ibuprofen
Interacting drugs - summary
NSAIDs +
+ Anticoagulants
Coadmnistration prolong prothrombin time (PT).
Consider effects of NSAIDs, on platelet function and gastric mucosa.
Monitor PT and patients closely,
+ ACE inhibitors
Antihypertensives effects of captopril blunted or completely abolished
by indomethacin
+ Beta blockers
Antihypertensive effects of beta-blockers impaired.
Sulindac and naproxen did not affect atenolol.
+ Cyclosporine
Naphrotoxicity of both agents increased
+ Digoxin
Ibuprofen and indomethicin increase digoxin levels
+ Dypridamole
Indomethicin and dipyridamole coadministration may agument
water retension.
+ Hydantoins
Serum phenytoin levels increased, resulting in increase in
pharmacologic and toxic effects of phenytoin
+ Lithium
Serum lithium levels increased, however sulindac has no effect or
may decrease lithium levels
+ Loop diuretics
Effects of loop diuretics decreased
+ Methotrexate
Risks of methotrexate toxicity (eg Stomatitis,bone marrow suppression,
nephrotoxicity) increased
+ Penicillamine
Indomethacin increase bioavailabilty of penicillinamine
+ Sympathomimetics
Indomethacin and phenylpropanolamine coadministration result in
increased blood pressure
+ Thiazide diuretics
Decreased antihypertensive and diuretic action of thiazides occur with
concurrent indomethacin. Naproxen has also been implicated.
Sulindac may enhance effects of thiazides
+ NSAIDs
Cimetidine+
NSAIDs plasma concentrations increased or decreased by cimetidine,
Also, indomethacin and sulindac increased ranitidine and cimetidine
bioavailability
Probenecid +
Probenecid increase concentrations and possibly toxicity of the
NSAIDs
Salicylates +
Plasma concentrations of NSAIDs decreased by salicylates.
Avoid concomittant use, since it offers no therapeutic advantage
and significantly increase incidence of GI effects.
Dimethyl sulfoxide + DMSO + Sulindac
DMSO ( Dimethyl sulfoxide ) decrease the formation of active metabolite
of sulindac, resulting in a decreased therapeutc effect. with
Indication:
Adverse Reaction:
GI-
Nausea (with or without vomiting) ( 9% diclofenanc, etodolac, fenoprofen, fluribiprofen,
indomethicin, nabumetone , naproxen, oxaproxen sulindac, Ketoprofen > 3%,
Ketorolac 12%, meclofenamate 11%, tometin 11%
Vomiting - diclofenac < 1%, etodolac 3 %, fenoprofen 8%, flurbiprofen 1 to 3%
ketoprofen > 1%, ketorilac < 3%, nabumetone 3%, naproxen < 1%,
oxaproxen < 3%, piroxicam < 1%, tolmetrin 9%
Diarrhea - diclofenac 8%, etodolac 7%, flurbiprofen7%,
indomethicin < 3%, ketoprofen > 3%, ketorolac 7%, meclofenamate 30%,
mefenamic acid 5%, nabumetone 14%, naproxen < 3%, oxaproxen 8%,
piroxicam 3%, sulindac 9%, tolmetrin 9%
Constipation- diclofenac 9%, etodolac 3%, fenoprofen 9%, flurbiprofen 3%
ibuprofen < 3%, indomethicin < 3%, ketoprofen > 3%,ketorolac <3% ,
.meclofenamate 3%, nabumetone 9%, naproxen 9 %, oxaproxen 9%,
piroxicam 3%, sulindac 9%, tolmetrin <3 %
Abdominal distress/cramps, pain - diclofenac 9%, etodolac 9%,fenoprofen < 3%,
flurbiprofen < 3%, indomethicin < 3%, ketoprofen > 3%, ketorolac 13 %,
meclofenamate 9%, nabumetone 12%, naproxen 9 %, oxaproxen <3 %,
piroxicam 3%, sulindac 10%, tolmetrin 9%
Dyspepsia- diclofenac 9%, etodolac 10%, fenoprofen 9 %, flurbiprofen 9%,
ibuprofen 9 %, indomethicin 9%, ketoprofen 11%, ketorolac 12 %,
nabumetone 13%, naproxen 9 %, oxaproxen 9%, piroxicam 9%,
sulindac 9%, tolmetrin 9%
Flatulence- diclofenac 3%, etodolac 9%, fenoprofen <3 %, flurbiprofen 3%
indomethicin < 1%, ketoprofen > 3%, ketorolac <3 %, meclofenamate 9%,
nabumetone 9%, oxaproxen < 3 %, piroxicam 3%, sulindac 3%,
tolmetrin 9%
Anorexia - etodolac < 1%, fenoprofen <3 %, indomethicin < 1%, ketoprofen > 1%
meclofenamate 1 to 3%, nabumetone < 1%, oxaproxen < 3 %, piroxicam < 3%,
sulindac 1 to 3%, tolmetrin 1 to 3%
Stomatisis - diclofenac < 1%, etodolac < 1%, flurbiprofen <1%, indomethicin < 1%,
ketoprofen > 1%, ketorolac <3 %, meclofenamate 1 to 3%, nabumetone 1 to 3%
naproxen < 3 %, oxaproxen < 1 %, piroxicam 1 to 3%, sulindac <1%, tolmetrin <1%
CNS- dizziness( 3 to 9% -flurbiprufen and diclofenac 1% to 3%)
headaches, (ketorolac 17%, fenoprofen 15%, indomethicin 11%, diclofenac , flurbiprufen,
meclofenamate , nabumetone, naproxen and tolmetin 3 to 9%, ketoprofen > 3%)
somnolence/drowsiness, (fenoprofen 15%, naproxen 3 to 9% , oxaprozin < 3% )
lightheadedness, verigo, nervousness, excitation, paresthesia, peripheral neuropathy,
tremor, convusions, aggravation of epilepsy and parkinsonism, myalgia, muscle weakness,
asthenia, somnolence, malaise, fatigue, insomnia, confusion, inability to concentrate,
depression, emotional lability.
Cardiovascular- congestive heart failure, exacerbation of angitis, hypotension, hypertension, palpitations,
arrhythmias, tachycardia, vasodilation, peripheral edema anf fliud retention, chest pain,
sinus bradycardia, peripheral vasculitis
Renal- hematuria, cystitis, urinary tract infection, azotemia, nocturia, proteinuria, elevated BUN,
increased serum creatinine, decreased creatinine clearance, polyuria, dysuria, urinary
frequency, pyuria, oliguria, anuria, renal insufficiency, including renal failure, acute renal
failure in patients with impaired renal function, renal papilary necrosis,nephrosis,
nephrotic syndrome,glomerular and intestinal nephritis, urinary casts.
Hematologic- neutropenia, eosinophillia, leukopenia, pancytopenia, thrombocytopenia, agranulocytosis,
garnulocytopenia, aplastic anemi, hemolytic anemia, decreases in hemoglobin and
hematrocrit, anemia secondary to obvious or ocult bleding, hypocaogulability, epistaxis,
menomerorrhagia, menorrhagia,hemorrhage, bruising, bone marrow depression, mild
hepatic toxicity.
Special senses- visual disrurbances,blurred vision, photophobia, amblyopia, scotoma, swollen ordry
irritated eyes, corneal deposits, retinal degeneration, retinal haemorrhage and
pigmentaion change, conjuntivitis,iritis, reversible loss of color vision, hearing dusturbances
or loss, deafness, ear pain, chanage in taste (metallic or bitter ) diplopia, optic neuritis,
catracts, tinnitus, parosmia
Hypersentivity- asthma, amaphylaxis, acute respiratory distress, rapid fall in blood pressure resembling
shock-like state angioedema, dyspnea, angitis
Dermatologic- rash, erythema, urticaria, desquamation, vesilobullous eruptions, cutaneous vasculitis,
toxic epidermal necrolysis, exfoliative dermatitis, erythema mutiforme, Stevens-Johnson
syndrome, erythema nodosum, angioneurotic edema, ecchymosis, petechiae, purpura
alopecia, pruritus, eczema, skindiscoloration, hyperpigmentation,oncychosis,
photosentivity, skin irritation, peeling, rash/dermatitis including maculopapular type.
Metabolic- decreased or increased appetite, weight decrease or increase, glycosuria, hyperglycemia,
hyperkalemia, hyponatremia, flushing or sweating, menstrual disorders impotence, vaginal
bleeding, diabetes mellitus.
Miscellaneous- thirst, pyrexia, (fever and chills) sweating, breast changes, gynaecomastia, muscle
cramps, facial edema, serum sickness, pain, aseptic menignitis.
Contra-Indications:
Active petic ulcer,Hypersens,recent GI bleeding disorders, neonates.
Warnings-
GI effects- serious GI toxicity such as bleeding, ulceration and perforation can occur at any time, with or without warning symptoms, in patients treated chronically with NSAIS therapy
Although minor upper GI problems (eg dyspepsia) are common, usually developing early in therapy remain alert for uncertion and bleeding in patients treated chronically with NSAID even in absence of previous GI tract symptoms
Do not give indomethicin or sulindac to patients with active GI lesions or a history of recurrent GI lesions, unless the very high risk is warranted risk and patients can be monitored very closely
If diarrhea occurs with mefanamic acid or meclofenamate reduce dosage or temporarily discontinue use.
CNS effects- indomethicin may aggravate depression or other psychiatric disturbances, epilepsy, and parkinsonism, use with considerable caution.
Some of these agents may cause headache ( highest incidence with fenoprofen, indomethicin, and ketorolac ). If headache pesists despite dosage reduction, discontinue use
Renal effects- acute renal insufficiency , intestinal nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur
Acute renal insufficiency - patients with preexisting renal disease or compromised renal pefusion are at greatest risk.
Renal function impairment- NSAID metabolites are eliminated primarily by kidneys, use with caution. Assess renal function before and during therapy. Monitor serum and creatinine clearance. Reduce dosage to avoid excessive accumulation
Hypersensitivity- A potentially fatal apparent hypersensitivity syndrome has occured with sulindac this syndrome may include constitutional symptoms, cutaneous findings, involvement of major organs or other less specific findings
Anaphylactoid reactions - these reactions have occurred in patients with aspirin hypersensitivity and in patients who continued with tolmetrin, then restarted it. These reactions appear to occur more often with tolmetrin than other NSAIDs not structurally related.
Elderly- age appears to increase the possibility of adverse reactions to NSAIDs. The risk of serious ulcer disease is increased in elderly patienrs (. 65 yerars of age) taking NSAIDs. This risk appears to increase with dose.
Pregnancy- avoid during pregnancy especially in the third trimester.
Lactation- do not use use in nursing mothers because of the effect on infants cardiovascular system.
Children- Safety and efficacy of NSAIDs in children are not established
Special precautions:
Asthma, renal or hepatic disorders, bleeding disorders, cardiovascular disease. Patients
receiving coumarin anticoagulants. Aspirin, NSAID induced allergy. Pregnancy.
Monitoring- serious GI tract ulceration and bleeding can occur without warning . Follow chronicaly treated patients for signs and symptoms of ulceration and bleeding , inform them of the importance of this follow-up.
Steroid dosage- if reduced or eliminated during therapy, reduce slowly and observe patient slowly for evidence of adverse effects.
Platelet aggregation- NSAID can inhibit paltelet aggregation,the effect is quantitatively less and shorter duration than seen with aspirin.Use with caution in persons with intrinsic coagulation defects and in those on anticoagulant therapy.
Hematologic effects- frequently determine hemoglobin values in patients with initial values < 10g/dl who are to receive long term threapy.
Cardiovascular effects- may cause fluid retention and peripheral edema. Use caution in compromised cardiac function hypertension or other conditions predisposing to fluid retention.
Ophthalmic effects- perform ophthalmic studies in patients who develop eye complaints during therapy.Effects include blurred or diminished vision, changes incolorvision, corneal deposits and retinal disturbances.
Infection- NSAIDs may mask the usual signs of infection. Use with extra care in the presence of existing controlled infection.
Hepatic effects- if symptoms or signs suggesting liver dysfunction or an abnormal test occurs, evaluate for more severe hepatic reactions. Discontinue treatment if abnormal test persist or worsen or if clinical signs and symptoms consistent wiith liver disease develop or if systemic manifestations occur (eg. eosinophillia)
Pancreatitis- has occured in patients receiving sulindac. If pancreatis is suspected discontinue drug, start supportive therapy and monitor closely.
Auditory effects- perform periodic auditory function tests during chronic fenoprofen therapy in patients with impaired hearing.
Dermatologic effects- promptly discontinue mefanamic acid if rash appears.
Concomittant therapy- do not use naproxen sodium and naproxen concomittantly, both drugs circulate as naproxen anion.
Photosentivity- may occur. Take protective measures.
Dosages/ Overdosage Etc:
Other Information:
Patient Information:
1. Side effects of NSAIDs can cause discomfort and rarely, more serious side effects such as GI bleeding which may result in hospitalisation and even fatalites. NSAIDs are often essential in manangement of arthiritis and have a major role in treating pain but they also may be commonly employed for less serious conditions. Appraise potential patients of potential risks.
2. Avoid aspirin and alcoholic beverages while taking medication.
3. If GI upset occurs, take with food, milk or antacids. For GI upset with tolmetin, use antacids other than sodium bicabonate, bioavailbility is affected by food and milk.
If GI symptoms persist, consult physician
4. May cause cause drowsiness, dizziness, or blurred vision, patients should observe caution while driving or peforming other tasks requiring alertness
5. Notify physician if skin rash, itching, visual disturbances, weight gain, edema, black stools, or persistent headache occurs.
6. Mefanamic acid and meclofenamate - if rash , diarrhea or other digestive problems occur, discontinue use and consult a physician
7. Ibuprofen ( otc use ) - do not take for > 3 days for fever or 10 days for pain, If these symptoms persist, worsen or if new symptoms develop, contact a physician
8. Allergies- Tell your doctor if you have ever had any unusual or allergic reaction to NSAID
or any other medicines e.g. Aspirin or other salicylates
9. Diet- Make sure your doctor knows if you are on any special diet, such as low-sodium
or low sugar. Some of these medicines contain certain sodium or sugar.
10. Pregnancy- If you are pregnant do not take any of these medicines including
non-prescription OTC drugs- ibuprofen or naproxen without dscussing its use with your doctor.
11. Breast feeding- Indomethicin- passes into breast milk and has been reported to cause unwanted effects in nursing babies. Meclofenamate- use not recommended.
12. Children-
Ibuprofen- ibuprofen has been tested in children 6 months of age and older
Not shown to cause any different side effects than they do in adults Indomethicin and
Tolmetin- indomethicin and tolmetin and have cause any different effects than they do in adults
Naproxen- studies in children have shown that skin rash may be more likely to occur.
Oxaprozin- oxaprozin has been used in children with arthiritis.
Phenylbutazone- use of phenylbutazone in children up to 15 years of age not recommened.
Other anti-inflammatory drugs- no specific information on use in children available.
13. Elderly- Certain side effects such as confusion, swelling of the face, feet or lower legs
or sudden decrease in the amount of urine may occur in elderly patients.
With phenylbutazone ,blood problems may also occur in the elderly.
13. Other medicines- Let your doctor know if you are taking any other medicines .e,g. Anticoagulants or
Cefamandole or Cefoperazone, Heparin - change of bleeding may be increased
14. Other medical problems- Make sure you tell your doctor, if you have any other medical
problems- Alcohol abuse or Bleeding problems or Colitis ,Crohns disease, diverticulitis
,stomach ulcer, or other stomach or intestinal problems - chance of side effects may
be increased
15 Missed dose- If you are taking the medicine regularly and you miss a dose, take it as
soon as possible. However ifis time for the next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.
17. Storage- Keep the medicines our of reach of children
Store the medicines away heat and direct light. Do not store tablets or capsules
in the bath room, in damp places near the kitchen sink .
Heat and moisture will cause the medicines to break down
Do not store out dated medicines or medicines no longer needed.
Make sure that all discarded medicines are kept out of reach of children
Pharmacology/ Pharmacokinetics:
Interaction with Food:
Delays absorption but not very significant
Pregnancy and lactation:
Pregnancy-
Category B- Ketoprofen, naproxen, flubiprofen, diclofenac. Category C- Etodolac, ketorolac, mefanamic acid, nabumetone, oxaprozin, tolmetin
Safety for use during pregnancy not established. Use is not recommended.
Lactation- Most NSAIDs are excreted in the breast milk.